Vasopressin receptor antagonists in the management of acute heart failure

Expert Opinion on Investigational Drugs

Volumn 14, Issue 5, 2005, Pages 593-600

  Tang, W H Wilson ^a   Bhavnani, Sanjeev ^a   Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute heart failure; Fluid retention; Pharmacological therapy; Vaptan; Vasopressin

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; CONIVAPTAN; FUROSEMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PLACEBO; RELCOVAPTAN; SR 149415; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; YM 218;

ACUTE HEART FAILURE; BLOOD VOLUME; BODY FLUID; CLINICAL TRIAL; DIURESIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; HEART HEMODYNAMICS; HOMEOSTASIS; HUMAN; HYPERVOLEMIA; META ANALYSIS; OSMOREGULATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASOCONSTRICTION; WEIGHT REDUCTION;

ACUTE DISEASE; ANIMALS; CARDIOVASCULAR AGENTS; DISEASE MANAGEMENT; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, VASOPRESSIN;

EID: 20344407294     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.5.593     Document Type: Review

References (52)

1. WEBER KT: Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. J. Am. Coll. Cardiol. (2004) 44(6):1308-1310.
2. ANDRONE AS, HRYNIEWICZ K, HUDAIHED A et al.: Relation of unrecognized hypervolaemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am. J. Cardiol. (2004) 93(10):1254-1259.
3. TURNER RA, PIERCE JG, VIGNEAUD V: The purification and the amino acid content of vasopressin preparations. J. Biol. Chem. (1951) 191:21-28.
4. GOLDSMITH SR: Vasopressin as vasopressor. Am. J. Med. (1987) 82(6):1213-1219.
5. MICHELL RH, KIRK CJ, BILLAH MM: Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem. Soc. Trans. (1979) 7(5):861-865.
6. 1a vasopressin receptor. J. Biol. Chem. (1994) 269(5):3304-3310.
7. 1b vasopressin receptor. J. Biol. Chem. (1994) 269(43):27088-27092.
8. BIRNBAUMER M, SEIBOLD A, GILBERT S et al.: Molecular cloning of the receptor for human antidiuretic hormone. Nature (1992) 357(6376):333-335.
9. CONWAY RS, NATELSON BH, CHEN WH, TING W. Enhanced coronary vasoconstriction in the Syrian myopathic hamster supports the microvascular spasm hypothesis. Cardiovasc. Res. (1994) 28(3):320-324.
10. 2- vasopressinergic receptors. Am. J. Physiol. (1988) 255(2 Part 2):H261-H265.
11. KHAYYAL MA, ENG C, FRANZEN D, BREALL JA, KIRK ES: Effects of vasopressin on the coronary circulation: reserve and regulation during ischemia. Am. J. Physiol. (1985) 248(4 Part 2):H516-H522.
12. NAITOH M, RISVANIS J, BALDING LC, JOHNSTON CI, BURRELL LM: Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc. Res. (2002) 54(1):51-57.
13. GOLDSMITH SR, FRANCIS GS, COWLEY AW Jr, GOLDENBERG IF, COHN JN: Haemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol. (1986) 8(4):779-783.
14. 1 receptor. Mol. Cell. Biochem. (1999) 195(1-2):93-98.
15. XU DL, MARTIN PY, OHARA M et al.: Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J. Clin. Invest. (1997) 99(7):1500-1505.
16. ISHIKAWA S: Urinary excretion of aquaporin-2 in pathological states of water metabolism. Ann. Med. (2000) 32(2):90-93.
17. FUNAYAMA H, NAKAMURA T, SAITO T et al.: Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int. (2004) 66(4):1387-1392.
18. 2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J. Am. Soc. Nephrol. (1999) 10(10):2165-2170.
19. 2 antagonist OPC-31260 in heart failure in the rat. Am. J. Physiol. (1998) 275 (1 Part 2): H176-H182.
20. SCHRIER RW, ABRAHAM WT. Hormones and hemodynamics in heart failure. N. Engl. J. Med. (1999) 341(8):577-585.
21. YAMANE Y: Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ. J. (1968) 32(5):745-759.
22. FRANCIS GS, BENEDICT C, JOHNSTONE DE et al.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 82(5):1724-1729.
23. GOLDSMITH SR, FRANCIS GS, COWLEY AW Jr, LEVINE TB, COHN JN: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. (1983) 1(6):1385-1390.
24. ROULEAU JL, PACKER M, MOYE L et al.: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll. Cardiol. (1994) 24(3):583-591.
25. SCHRIER RW, BICHET DG: Osmotic and nonosmotic control of vasopressin release and the pathogenesis of impaired water excretion in adrenal, thyroid, and oedemarous disorders. J. Lab. Clin. Med. (1981) 98(1):1-15.
26. ISHIKAWA S, GOLDBERG JP, SCHRIER DM, AISENBREY GA, SCHRIER RW. Interrelationship between subpressor effects of vasopressin and other vasoactive hormones in the rat. Miner. Electrolyte Metab. (1984) 10(3):184-189.
27. LEVINE TB, FRANCIS GS, GOLDSMITH SR, COHN JN: The neurohumoral and haemodynamic response to orthostatic tilt in patients with congestive heart failure. Circulation (1983) 67(5):1070-1075.
28. LEE WH, PACKER M: Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation (1986) 73(2):257-267.
29. ELLISON DH: The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann. Intern. Med. (1991) 114(10):886-894.
30. COOPER HA, DRIES DL, DAVIS CE, SHEN YL, DOMANSKI MJ: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation (1999) 100(12):1311-1315.
31. LEE CR, PATTERSON JH, GATTIS W: Renal dysfunction is common in patients with heart failure and preserved systolic function: Retrospective analysis of the digitalis investigational group (DIG) trial. Circulation (2003) 108(17):484 (Abstract 2220).
32. TSUTSUI T, TSUTAMOTO T, MAEDA K, KINOSHITA M: Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure. J. Cardiovasc. Pharmacol. (2001) 38(Suppl. 1):S81-S85.
33. BRATER DC: Diuretic therapy. N. Engl. J. Med. (1998) 339(6):387-395.
34. NICOD P, WAEBER B, BUSSIEN JP et al.: Acute haemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am. J. Cardiol. (1985) 55(8):1043-1047.
35. UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute haemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104(20):2417-2423.
36. BRATER DC, CHENNAVASIN P, SEIWELL R. Furosemide in patients with heart failure: shift in dose-response curves. Clin. Pharmacol. Ther. (1980) 28(2):182-186.
37. VARGO DL, KRAMER WG, BLACK PK et al.: Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin. Pharmacol. Ther. (1995) 57(6):601-609.
38. LEE CR, WATKINS ML, PATTERSON JH et al.: Vasopressin: a new target for the treatment of heart failure. Am. Heart J. (2003) 146(1):9-18.
39. 2 antagonist in men. J. Pharmacol. Exp. Ther. (1995) 272(2):546-551.
40. HIRANO T, YAMAMURA Y, NAKAMURA S, ONOGAWA T, MORI T: Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol. Exp. Ther. (2000) 292(1):288-294.
41. NAITOH M, SUZUKI H, MURAKAMI M et al.: Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol. (1994) 267(6 Part 2):H2245-H2254.
42. GHEORGHIADE M, GATTIS WA, O'CONNOR CM et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 291(16):1963-1971.
43. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107(21):2690-2696.
44. UDELSON JE: Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosimide, and their combination. J. Am. Coll. Cardiol. (2002) 39(Suppl. 5) (Abstract).
45. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur. J. Pharmacol. (1999) 376(3):239-246.
46. WADA K, FUJIMORI A, MATSUKAWA U et al.: Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur. J. Pharmacol. (2005) 507(1-3):145-151.
47. TONKON: Interaction between furosemide and oral conivaptan in patients with heart failure. Eur. Heart J. (1999) (Suppl.) (Abstract).
48. GOLDSMITH SR, FRANCIS GS, COWLEY AW Jr.: Arginine vasopressin and the renal response to water loading in congestive heart failure. Am. J. Cardiol. (1986) 58(3):295-299.
49. ECELBARGER CA, CHOU CL, LEE AJ et al.: Escape from vasopressin-induced antidiuresis: role of vasopressin resistance of the collecting duct. Am. J. Physiol. (1998) 274(6 Part 2):F1161-F1166.
50. RUSSELL SD, SELARU P, PYNE DA et al.: Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am. Heart J. (2003) 145(1):179-186.
51. FONAROW GC, ADAMS KF Jr, ABRAHAM WT, YANCY CW, BOSCARDIN WJ: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA (2005) 293(5):572-580.
52. FRANCIS GS, TANG WH: Visopressin receptor antagonists: will the 'vaptans' fulfill their promise? JAMA (2004) 291(16):2017-2018.